Os therapies awarded ost-her2 clinical trial data presentation at mib agents factor osteosarcoma conference

New york--(business wire)--os therapies, inc. (nyse-a: ostx), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the mib agents factor osteosarcoma conference to be held june 26-28, 2025 in salt lake city, utah. key data will be presented from the company's phase 2b clinical trial of ost-her2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma.
OST Ratings Summary
OST Quant Ranking